HALE DAVID F 4
4 · Oncternal Therapeutics, Inc. · Filed Feb 27, 2024
Insider Transaction Report
Form 4
HALE DAVID F
Director
Transactions
- Purchase
Common Stock
2024-02-23$9.04/sh+266$2,405→ 29,673 total(indirect: By LLC) - Purchase
Common Stock
2024-02-23$9.04/sh+714$6,455→ 714 total
Holdings
- 917(indirect: By Hale Trading Company)
Common Stock
Footnotes (1)
- [F1]The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.